Active
Small Business
Overview
- Legal name
- AN2 THERAPEUTICS, INC
- Registered location
- MENLO PARK, CA, USA
- Website
- Company website ↗
- Primary NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- Latest award activity
- Aug 18, 2026
Read company summary
AN2 THERAPEUTICS, INC is associated with UEI DD4FE2GE4L78 and CAGE 822Z2 in public federal records. AcornBids currently links 1 prime award totaling $9.2M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 325412 (Pharmaceutical Preparation Manufacturing). Its public SAM.gov registration lists MENLO PARK, CA, USA.
At a glance
Lifetime prime obligations$9.2M
Prime awards1
Awards with future end dates1
Top-agency concentration100.0%
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 8, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- AN2 THERAPEUTICS, INC
- UEI
- DD4FE2GE4L78
- CAGE
- 822Z2
- Registered address
- 1800 EL CAMINO REAL STE D, MENLO PARK, CA, 94027, USA
- Registration status
- Active
- Primary NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- SAM activation
- Jun 3, 2026
- Initial registration
- Mar 5, 2018
- Entity start
- Feb 15, 2017
- SAM updated
- Jun 3, 2026
- Registration expires
- Jun 1, 2027
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Research brief
Source facts
- Loaded prime-award records link 1 awards and $9,235,577 in reported obligations to this legal entity. Source
- Recorded awards include Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715); this classification is not proof of every company capability. Source
- An example award describes: DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS. Source
Federal award analysis
Net transaction obligations by federal fiscal period.
Selected transaction obligations$9.2M
Prime contracts
Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 1 of 1 selected awards. Select a period to explore its awards.
Funding change
Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.
| Measure | Reported value |
|---|---|
| Current period | Oct 1, 2025 – Sep 30, 2026 |
| Current obligations | $0 |
| Prior period | Oct 1, 2024 – Sep 30, 2025 |
| Prior obligations | $456.8K |
| Change | $-456.8K |
| Growth | -100.0% |
Where the work is performed
AKMEVTNHWAIDMTNDMNWIMINYMAORNVWYSDIAILINOHPANJCTRICAUTCONEMOKYWVVAMDDEAZNMKSARTNNCSCDCOKLAMSALGAHITXFL
State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.
Agencies
| Category | Period obligations | Awards |
|---|---|---|
| Department of Health and Human Services | $9.2M | 1 |
Offices
| Category | Period obligations | Awards |
|---|---|---|
| NATIONAL INSTITUTES OF HEALTH NIAID | $9.2M | 1 |
Naics
| Category | Period obligations | Awards |
|---|---|---|
| 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | $9.2M | 1 |
Psc
| Category | Period obligations | Awards |
|---|---|---|
| AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $9.2M | 1 |
Vehicles
| Category | Period obligations | Awards |
|---|---|---|
| Unclassified | $9.2M | 1 |
States
| Category | Period obligations | Awards |
|---|---|---|
| CA | $9.2M | 1 |
Set Asides
| Category | Period obligations | Awards |
|---|---|---|
| NO SET ASIDE USED. | $9.2M | 1 |
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75N93022C00059DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS. | Department of Health and Human Services | $9.2M | Sep 20, 2022 | Jul 31, 2027 |
Upcoming positioning windows
Modeled recompete windows are estimates, not announced solicitations or guarantees.
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Jun 3, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Mar 5, 2018 |
| Entity start | Feb 15, 2017 |
Registration classifications: Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 325412 — Pharmaceutical Preparation Manufacturing | Not reported |
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| STEPHEN PRIOR | Government business | Contact method not published | SAM registration | Not available |
| RIANNA STEFANAKIS | Alternate government business | Contact method not published | SAM registration | Not available |
| STEPHEN PRIOR | Electronic business | Contact method not published | SAM registration | Not available |
| RIANNA STEFANAKIS | Alternate electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 325412 — Pharmaceutical Preparation Manufacturing
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
1 awards
1 awards
1 awards
1 awards
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit